The breast cancer risk variants identified in genome-wide association studies explain only a small fraction of the familial relative risk, and the genes responsible for these associations remain largely unknown. To identify novel risk loci and likely causal genes, we performed a transcriptome-wide association study evaluating associations of genetically predicted gene expression with breast cancer risk in 122,977 cases and 105,974 controls of European ancestry. We used data from the Genotype-Tissue Expression Project to establish genetic models to predict gene expression in breast tissue and evaluated model performance using data from The Cancer Genome Atlas. Of the 8,597 genes evaluated, significant associations were identified for 48 at a Bonferroni-corrected threshold of P < 5.82 × 10 −6
B
reast cancer is the most common malignancy among women in many countries 1 . Genetic factors play an important role in its etiology [2] [3] [4] [5] . Since 2007, genome-wide association studies (GWAS) have identified approximately 170 genetic loci harboring common, low-penetrance variants for breast cancer [6] [7] [8] [9] [10] [11] [12] [13] , but these variants explain less than 20% of familial relative risk 7 . Most disease-associated risk variants identified by GWAS are located in non-protein-coding regions and are not in linkage disequilibrium with any nonsynonymous coding SNPs 14 . Many of these susceptibility variants are located in gene regulatory elements 15, 16 , and it has been hypothesized that many GWAS-identified associations may be driven by the regulatory function of risk variants on the expression of nearby genes. For breast cancer, recent studies have already shown that GWAS-identified associations at more than 15 loci are likely due to the effect of risk variants at these loci on regulating the expression of either nearby or more distal genes 7, 9, 10, 13, [17] [18] [19] [20] [21] [22] . However, for the large majority of the GWAS-identified breast cancer risk loci, the genes responsible for the associations remain unknown.
Several studies have reported that regulatory variants may account for a large proportion of disease heritability not yet discovered through GWAS [23] [24] [25] . Many of these variants may have a small effect size, and thus are difficult to identify in individual SNP-based GWAS, even with a large sample size. Applying gene-based approaches that aggregate the effects of multiple variants into a single testing unit may increase study power to identify novel disease-associated loci. Transcriptome-wide association studies (TWAS) systematically investigate the association of genetically predicted gene expression with disease risk, providing an effective approach to identify novel susceptibility genes [26] [27] [28] [29] . A recently performed TWAS including 15,440 cases and 31,159 controls reported significant associations for 5 genes with breast cancer risk 30 . However, the sample size of that study was relatively small and several reported associations were not significant after Bonferroni correction. Herein, we report results from a larger TWAS of breast cancer that used the MetaXcan method 26 to analyze summary statistics data from 122,977 cases and 105,974 controls of European descent from the Breast Cancer Association Consortium (BCAC).
Results
Gene expression prediction models. The study design is shown in Supplementary Fig. 1 . We used transcriptome and genotyping data A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer from 67 women of European descent included in the GenotypeTissue Expression (GTEx) project to build genetic models to predict RNA expression levels for each gene expressed in normal breast tissues, by applying the elastic net method (α = 0.5) with tenfold crossvalidation. Genetically regulated expression was estimated using variants within a 2 megabase (Mb) window flanking the respective gene boundaries, inclusive. SNPs with a minor allele frequency of at least 0.05 and included in the HapMap Phase 2 were used for model building. Of the models built for 12,696 genes, 9,109 showed a prediction performance (R 2 ) of at least 0.01 (≥ 10% correlation between predicted and observed expression). For genes for which the expression could not be predicted well using this approach, we built models using only SNPs located in the promoter or enhancer regions, as predicted using three breast cell lines in the Roadmap Epigenomics Project/Encyclopedia of DNA Elements Project. This approach leverages information from functional genomics and reduces the number of variants for variable selection, therefore potentially improving statistical power. This enabled us to build genetic models for an additional 3,715 genes with R 2 ≥ 0.01. Supplementary Table  1 provides detailed information regarding the performance threshold and types of model built. Overall, genes that were predicted with R 2 ≥ 0.01 in GTEx data were also predicted well in The Cancer Genome Atlas (TCGA) tumor-adjacent normal tissue data (correlation coefficient of 0.55 for R 2 in two data sets; Supplementary  Fig. 2 ). On the basis of model performance in GTEx and TCGA, we prioritized 8,597 genes for analyses of the associations between predicted gene expression and breast cancer risk using the following criteria: genes with a model prediction R 2 ≥ 0.01 in the GTEx set (10% correlation) and a Spearman's correlation coefficient of ≥ 0.1 in the external validation experiment; genes with a prediction R 2 ≥ 0.09 (30% correlation) in the GTEx set regardless of their performance in the TCGA set; genes with a prediction R 2 ≥ 0.01 in the GTEx set (10% correlation) that could not be evaluated in the TCGA set because of a lack of data.
Associations of predicted expression with breast cancer. Using the MetaXcan method 26 , we performed association analyses to evaluate predicted gene expression and breast cancer risk using the metaanalysis summary statistics of SNPs generated for 122,977 cases and 105,974 controls of European ancestry included in BCAC. For the A full list of authors and affiliations appears at the end of the paper. majority of the tested genes, most of the SNPs selected for prediction models were used for the association analyses (for example, ≥ 80% predicting SNPs used for 95.6% of the tested genes). Lambda 1,000 (λ 1,000 ), a standardized estimate of the genomic inflation scaling to a study of 1,000 cases and 1,000 controls, was 1.004 in our study (quantile-quantile (QQ) plot presented in Supplementary Fig. 3a) . Of the 8,597 genes evaluated, we identified 179 whose predicted expression was associated with breast cancer risk at P < 1.05 × 10 −3 , a false discovery rate (FDR)-corrected significance level (Fig. 1 and  Supplementary Table 2 ). Of these, 48 showed a significant association at the Bonferroni-corrected threshold of P ≤ 5.82 × 10 −6 (Fig. 1  and Tables 1-3) , including 14 genes located at 11 loci that are 500 kb away from any risk variant identified in previous GWAS (Table 1 ). An association between lower predicted expression and increased breast cancer risk was detected for LRRC3B (3p24.1), SPATA18 (4q12), UBD (6p22.1), MIR31HG (9p21.3), RIC8A (11p15.5), B3GNT1 (11q13.2), GALNT16 (14q24.1) and MAN2C1 and CTD-2323K18.1 (15q24.2). Conversely, an association between higher predicted expression and increased breast cancer risk was identified for ZSWIM5 (1p34.1), KLHDC10 (7q32.2), RP11-867G23.10 (11q13.2), RP11-218M22.1 (12p13.33) and PLEKHD1 (14q24.1). The remaining 34 associated genes are located at known breast cancer susceptibility loci (Tables 2 and 3 ). Among them, 23 have not yet been implicated as genes responsible for association signals identified at these loci through expression quantitative trait loci (eQTL) and/ or functional studies, and do not harbor GWAS-or fine-mappingidentified risk variants ( 
10
) have been reported as potential causal genes at breast cancer susceptibility loci or harbor GWAS-or fine-mapping-identified risk variants (Table 3) . Except for RP11-73O6.3 and L3MBTL3, there was no evidence of heterogeneity (I 2 < 0.2) across the iCOGS, OncoArray and GWAS data sets included in our analyses (Supplementary Table 3 ). Overall, we identified 37 novel susceptibility genes for breast cancer and confirmed 11 genes known to potentially play a role in breast cancer susceptibility.
To determine whether the associations between predicted gene expression and breast cancer risk were independent of GWASidentified association signals, we performed conditional analyses adjusting for the GWAS-identified risk SNPs closest to the TWASidentified gene (Supplementary Table 4 ) 36 . We found that the associations for 11 genes (LRRC3B, SPATA18, KLHDC10, MIR31HG, RIC8A, B3GNT1, RP11-218M22.1, MAN2C1, CTD-2323K18.1 (Table 1) , ALK, CTD-3051D23.1 (Table 2) ) remained statistically significant at P < 5.82 × 10 −6 (Tables 1-3 ). This suggests that the expression of these genes may be associated with breast cancer risk independent of the GWAS-identified risk variant(s). For nine of the genes (SPATA18, KLHDC10, MIR31HG, RIC8A, RP11-218M22.1, MAN2C1, CTD-2323K18.1 (Table 1) , ALK and CTD-3051D23.1 (Table 2) ), the significance of the association remained essentially unchanged, suggesting that these associations may be entirely independent of GWAS-identified association signals.
Of the 131 genes showing an association at 5.82 × 10 −6
< P < 1.05 × 10 −3 (significant after FDR correction but not Bonferroni correction), 38 are located at GWAS-identified risk loci (Table 4) . Except for RP11-400F19. 8 , there was no evidence of heterogeneity in TWAS association (I 2 < 0.2) across the iCOGS, OncoArray and GWAS studies (Supplementary Table 3 , again suggesting that the association of these genes with breast cancer risk may be independent of the GWAS-identified association signals (Table 4) .
For 41 of the 48 associated genes that reached the Bonferronicorrected significance level, we obtained individual-level data from subjects included in the iCOGS (n = 84,740) and OncoArray (n = 112,133) data sets, which was 86% of the subjects included in the analysis using summary statistics (Supplementary Table 5 ).
The results from the analysis using individual-level data were very similar to those described above using MetaXcan analyses (Pearson correlation of Z scores was 0.991 for iCOGS data and 0.994 for OncoArray data), although not all associations reached the Bonferroni-corrected significance level, possibly due to a smaller sample size (Supplementary Table 5 ). Conditional analyses using individual-level data also revealed consistent results compared with analyses using summary data. We found that for several genes within the same genomic region, their predicted expression was correlated with each other (Tables 1-3 ). The associations between predicted expression of PLEKHD1 and ZSWIM5 and breast cancer risk were largely influenced by their corresponding closest risk variants identified in GWAS, although these risk variants are > 500 kb away from these genes ( Table 1) . There were significant correlations of rs999737 and rs1707302 with genetically predicted expression of PLEKHD1 (r = − 0.47 in the OncoArray data set and − 0.48 in the iCOGS data set) and ZSWIM5 (r = 0.50 in the OncoArray data set and 0.51 in the iCOGS data set), respectively.
INQUISIT algorithm scores. For the 48 associated genes after Bonferroni correction, we assessed their integrated expression quantitative trait and in silico prediction of GWAS target (INQUISIT) scores 7 to assess whether there is other evidence beyond the scope of eQTL for supporting our TWAS-identified genes as candidate target genes at GWAS-identified loci. The detailed methodology for INQUISIT scores have been described elsewhere 7 . In brief, a score for each gene-SNP pair is calculated across categories representing potential regulatory mechanismsdistal or proximal gene regulation (promoter). Features contributing to the score are based on functionally important genomic annotations such as chromatin interactions, transcription factor binding and eQTLs. Compared with evidence from eQTL alone, INQUISIT scores incorporate additional lines of evidence, including distal regulations. The INQUISIT scores for our identified genes are shown in Supplementary Table 6 . Except for UBD with a very low score in the distal regulation category (0.05), none of the genes at novel loci ( Table 1) showed evidence of being potential target genes for GWAS-identified breast cancer susceptibility loci. This is interesting and within the expectation since these genes may represent novel association signals. There was evidence . The blue line represents P = 1.00 × 10 Table 2 , and all 11 genes listed in Table 3 , may be target genes for risk variants at these loci (Supplementary Table 6 and ZNF404, the INQUISIT scores were not derived only from eQTL data, providing orthogonal support for these genes. For these loci, the associations of candidate causal SNPs with breast cancer risk may be mediated through these genes. This is in general consistent with the findings from the conditional analyses.
Pathway enrichment analyses. Ingenuity Pathway Analysis (IPA) 37 suggested potential enrichment of cancer-related functions for the identified protein-coding genes (Supplementary Table 7 ). The top canonical pathways identified included apoptosis-related pathways (granzyme B signaling (P = 0.024) and cytotoxic T-lymphocytemediated apoptosis of target cells (P = 0.046)), immune system pathways (inflammasome pathway (P = 0.030)) and tumoricidal function of hepatic natural killer cells (P = 0.036). The identified pathways are largely consistent with previous findings 7 . For the associated long non-coding RNAs (lncRNAs), pathway analysis of their highly co-expressed protein-coding genes also revealed potential over-representation of cancer-related functions (Supplementary Table 7 ).
In vitro assays of gene functions. To assess the function of genes whose high predicted expression levels were associated with increased breast cancer risk, we selected 13 genes for knockdown experiments in breast cells: ZSWIM5, KLHDC10, RP11-218M22.1 and PLEKHD1 (Table 1) , UBLCP1, AP006621.6, RP11-467J12. 4 , CTD-3032H12.1 and RP11-15A1.7 (Table 2) , and ALS2CR12, RMND1, STXBP4 and ZNF404 ( Table 3) . As negative controls, we selected B2M, ARHGDIA and ZAP70 using the criteria: ≥ 2 Mb from any known breast cancer risk locus; not an essential gene in breast cancer 38, 39 ; and not predicted to be a target gene in INQUISIT. In addition, as positive controls, we included PIDD1 (Table 4) 7 , NRBF2 20 and ABHD8
22
, which have been functionally validated as target genes at breast cancer risk loci. We performed quantitative PCR (qPCR) on a panel of three 'normal' mammary epithelial and 15 breast cancer cell lines to analyze their expression levels ( Supplementary Fig. 4 and Supplementary Table 8 ). All 19 genes were expressed in the normal mammary epithelial line 184A1 40 and the luminal breast cancer cell lines, MCF7 and T47D, so we used these cell lines for the proliferation assay, and MCF7 for the colony-formation assay 41 . We also evaluated SNX32, ALK and BTN3A2 by qPCR, but they were not expressed in T47D and MCF7 cells; therefore, they were not evaluated further. It was difficult to design siRNAs against RP11-867G23.1 and RP11-53O19.1 because they both have multiple transcripts with limited, GC-rich regions in common. We did not include RPLP2 because it is already known to be an essential gene for breast cancer survival 39 . Knockdown of the 19 tested genes was achieved by siRNA (Supplementary Table 9 ) and the knockdown efficiency was calculated in 184A1, MCF7 and T47D for each siRNA pair. Robust knockdown of the gene of interests (GOI) was validated by qPCR with the majority of the siRNAs ( Supplementary Fig. 5 ).
To evaluate the survival and proliferation ability of cells following gene interruption, we used an IncuCyte to quantify cell proliferation in real time and quantified the corrected proliferation of cells with knockdown of GOI in comparison to that of cells with non-target control (NTC) siRNA. As expected, knockdown of the three negative control genes (B2M, ARHGDIA and ZAP70) did not significantly change cell proliferation in any of the three cell lines ( Fig. 2a and Supplementary Fig. 6 ). However, with the exception of UBLCP1, RMND1 and STXBP4, knockdown of all other genes (11 TWAS-identified genes along with 2 known genes, ABHD8 and NRBF2) resulted in significantly decreased cell proliferation in 184A1 normal breast cells, with KLHDC10, PLEKHD1, RP11-218M22.1, AP006621.6, ZNF404, RP11-467J12. 4 , CTD-3032H12.1 and STXBP4 showing a similar effect in one or both cancer cell lines. 
Discussion
This is the largest study to systematically evaluate associations of genetically predicted gene expression across the human transcriptome with breast cancer risk. We identified 179 genes showing a significant association at the FDR-corrected significance level. Of these, 48 genes showed an association at the Bonferroni-corrected threshold, including 14 at genomic loci that have not previously been implicated for breast cancer risk. Of the 34 genes located at known risk loci, 23 have not previously been shown to be the targets of GWAS-identified risk SNPs at corresponding loci and do not harbor any risk SNPs. Our study provides substantial new information to improve the understanding of genetics and etiology for breast cancer.
It is possible that TWAS-identified genes may be associated with breast cancer through their correlation with disease causal genes. To determine the potential functional significance of TWAS-identified genes and provide evidence for causal inference, we knocked down 13 genes for which high predicted levels of expression were associated with an increased breast cancer risk, in one normal and two breast cancer cell lines, and measured the effect on proliferation and CFE. Although there was some variation between cell lines, knockdown of 11 of the 13 genes showed an effect in at least one cell line, particularly on proliferation in 184A1 normal breast cells; the effects were strongest and most consistent for the lncRNAs RP11-218M22.1, RP11-467J12. 4 and CTD-3032H12.1. The observation of a more consistent effect in the normal breast cell line compared with the cancer cell lines is not surprising as cancer cell lines have increased capacity to handle gene interference through mutations that enhance cell survival. Rewiring of pathways and compensatory mechanisms is a hallmark of cancer. Knockdown of PIDD1, NRBF2 and ABHD8¸ for which breast cancer risk-associated haplotypes have been shown to be associated with increased expression in reporter assays 7, 20, 22 , affected either proliferation or CFE, supporting the results from this study.
Some of the genes with strong functional evidence from our study have been reported to have important roles in carcinogenesis. For example, RP11-467J12.4 (PR-lncRNA-1) is a p53-regulated lncRNA that modulates gene expression in response to DNA damage downstream of p53 42 . STXBP4 encodes syntaxin-binding protein 4, a scaffold protein that can stabilize and prevent degradation of an isoform of p63, a member of the p53 tumor suppressor family 43 . KLHDC10 encodes a member of the Kelch superfamily that can activate apoptosis signal-regulating kinase 1, contributing to oxidative stress-induced cell death 44 . Notably, another member of this superfamily, KLHDC7A, has recently been identified as the target gene at the 1p36 breast cancer risk locus 7 . SNX32, ALK and BTN3A2 are also likely susceptibility genes for breast cancer risk. However, their low or absent expression in our chosen breast cell lines prevented further functional analysis. ALK (anaplastic lymphoma kinase) copy-number gain and overexpression have been reported in aggressive and metastatic breast cancers 45 . Therapeutic targeting of ALK rearrangement has significantly improved survival in advanced ALK-positive lung cancer 46 , making it an attractive target for breast and other cancers. BTN3A2 is a member of the B7/butyrophilin-like group of Ig superfamily receptors modulating the function of T lymphocytes. Overexpression of BTN3A2in epithelial ovarian cancer is associated with higher infiltrating immune cells and a better prognosis 47 . Our analyses identified multiple genes with reduced expression associated with increased breast cancer risk. Among them, LRRC3B and CASP8 are putative tumor suppressors in multiple cancers, including breast cancer. Leucine-rich repeat-containing 3B (LRRC3B) is a putative LRR-containing transmembrane protein, which is frequently inactivated via promoter hypermethylation leading to inhibition of cancer cell growth, proliferation and invasion 48 . CASP8 encodes a member of the cysteine-aspartic acid protease family, which play a central role in cell apoptosis. Previous studies have suggested that caspase-8 may act as a tumor suppressor in certain types of lung cancer and neuroblastoma, although this function has not yet been demonstrated in breast cancer. Notably, several large association studies have identified SNPs at the 2q33/CASP8 locus associated with increased breast cancer risk 31, 49 . Consistent with our data, eQTL analyses showed that the risk alleles for breast cancer were associated with reduced CASP8 messenger RNA levels in both peripheral blood lymphocytes and normal breast tissue 31 . For seven of the genes listed in Tables 1 and 2 , we found some evidence from studies using tumor tissues, in vitro or in vivo experiments linking them to cancer risk (Supplementary Table 10) , although their association with breast cancer has not been demonstrated in human studies. For five of them (LRRC3B, SPATA18, RIC8A, ALK and CRHR1), previous in vitro and in vivo experiments and human tissue studies showed a consistent direction of the association as demonstrated in our studies. For two other genes (UBD and MIR31HG), however, results from previous studies were inconsistent, reporting both potential promoting and inhibiting effects on breast cancer development. Future studies are needed to evaluate the functions of these genes.
We included a large number of cases and controls, providing high statistical power for the association analysis. This large sample size enabled us to identify a large number of candidate breast cancer susceptibility genes, much larger than the number identified in a TWAS study with a sample size of about 20% of ours 30 . The previous study included subjects of different races, which could affect the results as linkage disequilibrium patterns differ by races. Of the five genes reported in that smaller TWAS that showed a suggestive association with breast cancer risk, the association for the RCCD1 gene was replicated in our study ( Table 3) . The other four genes (ANKLE1, DHODH, ACAP1 and LRRC25) were not evaluated in our study because of unsatisfactory performance of our breast-specific models for these genes that were built using the GTEx reference data set including only female European descendants.
A substantial proportion of SNPs included in OncoArray and iCOGS were selected from breast cancer GWAS and fine-mapping analyses, and thus these arrays were enriched for association signals with breast cancer risk. As a result, the overall λ value for the BCAC association analyses of individual variants is 1.26 after adjusting for population stratifications (QQ plot in Supplementary Fig. 3b ) 7 . The λ value for the associations of the ~257,000 SNPs included in the gene expression prediction models of the 8,597 genes tested in our association analysis is 1.40 (QQ plot in Supplementary Fig. 3c ). This higher λ value is perhaps expected because of a potential further enrichment of breast cancer-associated signals in the set of SNPs selected to predict gene expression. There could be additional gain of power (and thus a higher λ value) in TWAS as it aggregates the effect of multiple SNPs to predict gene expression and uses genes as the unit for association analyses. The lambda (λ) for our associated analyses of 8,597 genes was 1.51 (QQ plot presented in Supplementary Fig. 3a ) likely due to the potential enrichment and power gain as well as our large sample size, and the highly polygenic nature of the disease 7, 50 . Interestingly, high λ values were also found in recent large studies of other polygenic traits, such as body mass 36 ; all index SNPs in the corresponding region were adjusted for the conditional analyses.
index (λ = 1.99) and height (λ = 2.7) 51, 52 . The λ 1,000 , a standardized estimate of the genomic inflation scaling to a study of 1,000 cases and 1,000 controls, is 1.004 in our study.
The statistical power of our study is very high to detect associations for genes with a relatively high cis-heritability (h 2 ) ( Supplementary  Fig. 8 ). For example, our study has 80% statistical power to detect an association with breast cancer risk at P < 5.82 × 10 −6 with an odds ratio of 1.07 or higher per one standard deviation increase (or decrease) in the expression level of genes with an h 2 of 0.1 or higher. One limitation of our study is the small sample size for building gene expression prediction models, which may have affected the precision of model parameter estimates. We expect that models built with a larger sample size will identify additional association signals. We used samples from women of European origin in model building, given differences in gene expression patterns between males and females and in genetic architecture across ethnicities 53 . We also used gene expression data of tumor-adjacent normal tissue samples from European descendants in TCGA as an external validation step to prioritize genes for association analyses. Given potential somatic alterations in tumor-adjacent normal tissues, we retained all models showing a prediction R 2 of at least 0.09 in GTEx, regardless of their performance in TCGA. Not all genes have a significant hereditary component in expression regulation, and thus these genes could not be investigated in our study. For example, previous studies have provided strong evidence to support a significant role of the TERT, ESR1, CCND1, IGFBP5, TET2 and MRPS30 genes in the etiology of breast cancer. However, expression of these genes cannot be predicted well using the data from female European descendants included in the GTEx and thus they were not included in our association analyses. Supplementary Table 11 summarizes the performance of prediction models and association results for breast cancer target genes reported previously at GWAS-identified loci.
In summary, our study has identified multiple gene candidates that can be further functionally characterized. The silencing experiments we performed suggest that many of the genes identified are likely to mediate risk of breast cancer by affecting proliferation or CFE, two hallmarks of cancer. Further investigation of genes identified in our study will provide additional insight into the biology and genetics of breast cancer.
URLs. GTEx protocol, http://www.gtexportal.org/home/documentationPage; Gencode V19 annotation file, http://www.gencodegenes. org/releases/19.html; HaploReg, http://archive.broadinstitute.org/ mammals/haploreg/data/; OncoArray, http://epi.grants.cancer.gov/ oncoarray/.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0132-x. . P values were determined by one-way ANOVA followed by Dunnett's multiple-comparisons test: *P value < 0.05. NTC: non-target control.
Building of gene expression prediction models. We used transcriptome and highdensity genotyping data from the GTEx study to establish prediction models for genes expressed in normal breast tissues. Details of the GTEx have been described elsewhere 54 . Genomic DNA samples obtained from study subjects included in the GTEx were genotyped using Illumina OMNI 5M or 2.5M SNP Array and RNA samples from 51 tissue sites were sequenced to generate transcriptome profiling data. Genotype data were processed according to the GTEx protocol (see the URLs section). SNPs with a call rate < 98%, with differential missingness between the two array experiments (5M/2.5M Arrays), with Hardy-Weinberg equilibrium P value < 10 −6 (among subjects of European ancestry) or showing batch effects were excluded. One Klinefelter individual, three related individuals and a chromosome 17 trisomy individual were also excluded. The genotype data were imputed to the Haplotype Reference Consortium reference panel 55 using Minimac3 for imputation and SHAPEIT for prephasing 56, 57 . SNPs with high imputation quality (r 2 ≥ 0.8), minor allele frequency ≥ 0.05 and included in the HapMap Phase 2 version were used to build expression prediction models. For gene expression data, we used reads per kilobase per million (RPKM) units from RNA-SeQC 58 . Genes with a median expression level of 0 RPKM across samples were removed, and the RPKM values of each gene were log 2 transformed. We performed quantile normalization to bring the expression profile of each sample to the same scale, and performed inverse quantile normalization for each gene to map each set of expression values to a standard normal. We adjusted for the top ten principal components derived from genotype data and the top 15 probabilistic estimation of expression residual factors to correct for batch effects and experimental confounders in model building 59 . Genetic and transcriptome data from 67 female subjects of European descent without a prior breast cancer diagnosis were used to build gene expression prediction models for this study.
We built an expression prediction model for each gene by using the elastic net method as implemented in the glmnet R package, with α = 0.5, as recommended earlier 27 . The genetically regulated expression for each gene was estimated by including variants within a 2 Mb window flanking the respective gene boundaries, inclusive. Expression prediction models were built for protein-coding genes, lncRNAs, microRNAs (miRNAs), processed transcripts, immunoglobulin genes and T-cell receptor genes, according to categories described in the Gencode V19 annotation file (see the URLs section). Pseudogenes were not included in the present study because of potential concerns of inaccurate calling 60 . Tenfold cross-validation was used to validate the models internally. Prediction R 2 values (the square of the correlation between predicted and observed expression) were generated to estimate the prediction performance of each of the gene prediction models established.
For genes that cannot be predicted well using the above approach, we built models using only SNPs located in predicted promoter or enhancer regions in breast cell lines. This approach reduces the number of variants for model building, and thus potentially improves model accuracy, by increasing the ratio of sample size to effective degrees of freedom. SNP-level annotation data in three breast cell lines, namely breast myoepithelial primary cells (E027), breast variant human mammary epithelial cells (vHMEC) (E028) and HMEC mammary epithelial primary cells (E119) in the Roadmap Epigenomics Project/Encyclopedia of DNA Elements Project 16 , were downloaded from HaploReg (Version 4.0, assessed on December 6, 2016) (see the URLs section). SNPs in regions classified as promoters (TssA, TssAFlnk), enhancers (Enh, EnhG) or regions with both promoter and enhancer signatures (ExFlnk) according to the core 15 chromatin state model 16 in at least one of the cell lines were retained as input SNPs for model building.
Evaluating performance of gene expression prediction models using TCGA data. To assess further the validity of the models, we performed external validation using data generated in tumor-adjacent normal breast tissue samples obtained from 86 European-ancestry female breast cancer patients included in the TCGA. Genotype data were imputed using the same approach as described for GTEx data. Expression data were processed and normalized using a similar approach as described above. The predicted expression level for each gene was calculated using the model established using GTEx data and then compared with the observed level of that gene using the Spearman's correlation.
Evaluating statistical power for association tests. We conducted a simulation analysis to assess the power of our TWAS analysis. Specifically, we set the number of cases and controls to be 122,977 and 105,974, respectively, and generated the gene expression levels from the empirical distribution of predicted gene expression levels in the BCAC. We calculated statistical power at P < 5.82 × 10 −6 (the significance level used in our TWAS) according to cis-heritability (h 2 ), which we aim to capture using gene expression prediction models (R 2 ). The results based on 1,000 replicates are summarized in Supplementary Fig. 8 . On the basis of the power calculation, our TWAS analysis has 80% power to detect a minimum odds ratio of 1.11, 1.07, 1.05, 1.04 or 1.03 for breast cancer risk per one standard deviation increase (or decrease) in the expression level of a gene whose cis-heritability is 5%, 10%, 20%, 40% or 60%, respectively.
Association analyses of predicted gene expression with breast cancer risk. We used the following criteria to select genes for the association analysis: with a model prediction R 2 of ≥ 0.01 in GTEx and a Spearman's correlation coefficient of ≥ 0.1 in TCGA; with a prediction R 2 of ≥ 0.09 in GTEx regardless of the performance in TCGA; with a prediction R 2 of ≥ 0.01 in GTEx but unable to be evaluated in TCGA. The second group of genes was selected because some gene expression levels might have changed in TCGA tumor-adjacent normal tissues, and thus it is anticipated that some genes may show low prediction performance in TCGA data due to the influence of tumor growth 61, 62 . Overall, a total of 8,597 genes met the criteria and were evaluated for their expression-trait associations.
To identify novel breast cancer susceptibility loci and genes, the MetaXcan method, as described elsewhere, was used for the association analyses 26 . Briefly, the formula:
was used to estimate the Z score of the association between predicted expression and breast cancer risk. Here w lg is the weight of SNP l for predicting the expression of gene g, β l and β se( ) l are the GWAS association regression coefficient and its standard error for SNP l, and σ l andσ g are the estimated variances of SNP l and the predicted expression of gene g, respectively. Therefore, the weights for predicting gene expression, GWAS summary statistics results, and correlations between SNPs included in the prediction models are the input variables for the MetaXcan analyses. For this study, we estimated correlations between SNPs included in the prediction models using the phase 3, 1000 Genomes Project data focusing on European population.
For the association analysis, we used the summary statistics data for genetic variants associated with breast cancer risk generated in 122,977 breast cancer patients and 105,974 controls of European ancestry from the BCAC. The details of the BCAC have been described elsewhere 7, 9, 13, 63, 64 . Briefly, 46,785 breast cancer cases and 42,892 controls of European ancestry were genotyped using a custom Illumina iSelect genotyping array (iCOGS) containing ~211,155 variants. A further 61,282 cases and 45,494 controls of European ancestry were genotyped using the OncoArray including 570,000 SNPs (see the URLs section). Also included in this analysis were data from 9 GWAS studies including 14,910 breast cancer cases and 17,588 controls of European ancestry. Genotype data from iCOGS, OncoArray and GWAS were imputed using the October 2014 release of the 1000 Genomes Project data as a reference. Genetic association results for breast cancer risk were combined using inverse-variance fixed-effect meta-analyses 7 . For our study, only SNPs with imputation r 2 ≥ 0.3 were used. All participating BCAC studies were approved by their appropriate ethics review boards. Relevant ethical regulations were complied with. This study was approved by the BCAC Data Access Coordination Committee.
Lambda 1,000 (λ 1,000 ) was calculated to represent a standardized estimate of the genomic inflation scaling to a study of 1,000 cases and 1,000 controls, using the following formula: λ 1,000 = 1 + (λ obs − 1) × (1/n cases + 1/n controls )/ (1/1,000 cases + 1/1,000 controls ) (refs 65, 66 ). We used a Bonferroni-corrected P threshold of 5.82 × 10 −6 (0.05/8,597) to determine a statistically significant association for the primary analyses. To identify additional gene candidates at previously identified susceptibility loci, we also used an FDR-corrected P threshold of 1.05 × 10 −3 (FDR ≤ 0.05) to determine a significant association. Associated genes with an expression of > 0.1 RPKM in fewer than 10 individuals in GTEx data were excluded as the corresponding prediction models may not be stable.
To determine whether the predicted expression-trait associations were independent of the top signals identified in previous GWAS, we performed GCTA-COJO analyses developed in an earlier study 36 to calculate association betas and standard errors of variants with breast cancer risk after adjusting for the index SNPs of interest. We then re-ran the MetaXcan analyses using the association statistics after conditioning on the index SNPs. This information was used to determine whether the detected expression-trait associations remained significant after adjusting for the index SNPs.
For 41 identified associated genes at the Bonferroni-corrected threshold, we also performed analyses using individual-level data in the iCOGS (n = 84,740) and OncoArray (n = 112,133) data sets. We generated predicted gene expression using predicting SNPs (Supplementary Table 12 ), and then assessed the association between predicted gene expression and breast cancer risk adjusting for study and nine principal components in the iCOGS data set, and country and the first ten principal components in the OncoArray data set. Conditional analyses adjusting for index SNPs were performed to assess the potential influence of reported index SNPs on the association between predicted gene expression and breast cancer risk. Furthermore, we evaluated whether the predicted expression levels of genes within a same genomic region were correlated with each other by using the OncoArray data.
INQUISIT algorithm scores for TWAS-identified genes. To evaluate whether there are additional lines of evidence supporting the identified genes as putative target genes of GWAS-identified risk SNPs beyond the scope of eQTL, we assessed their INQUISIT algorithm scores, which have been described elsewhere 7 . Briefly, this approach evaluates chromatin interactions between distal and proximal regulatory transcription-factor-binding sites and the promoters at the risk regions using Hi-C data generated in HMECs 67 and chromatin interaction analysis by paired end tag in MCF7 cells. This could detect genome-wide interactions brought about by, or associated with, CCCTC-binding factor (CTCF), DNA polymerase II (POL2) and estrogen receptor (ER), all involved in transcriptional regulation 67 . Annotation of predicted target genes used the Integrated Method for Predicting Enhancer Targets (IM-PET) 68 , the Predicting Specific Tissue Interactions of Genes and Enhancers (PreSTIGE) algorithm 69 , Hnisz 70 and FANTOM 71 . Features contributing to the scores are based on functionally important genomic annotations such as chromatin interactions, transcription factor binding and eQTLs. The detailed information for the INQUISIT pipeline and scoring strategy has been included in a previous publication 7 . In brief, besides assigning integral points according to different features, we also set up-weighting and downweighting criteria according to breast cancer driver genes, topologically associated domain boundaries and gene expression levels in relevant breast cell lines. Scores in the distal regulation category range from 0 to 7, and in the promoter category from 0 to 4. A score of 0 represents that no evidence was found for regulation of the corresponding gene.
Functional enrichment analysis using IPA. We performed functional enrichment analysis for the identified protein-coding genes reaching the Bonferroni-corrected association threshold. To assess the potential functionality of the identified lncRNAs, we examined their co-expressed protein-coding genes determined using expression data for normal breast tissue of European females in GTEx. Spearman's correlations between protein-coding genes and identified lncRNAs of ≥ 0.4 or ≤ − 0.4 were used to indicate a high co-expression. Canonical pathways, top associated diseases and biofunctions, and top networks associated with genes of interest were estimated using IPA software 37 .
Gene expression in breast cell lines. Total RNA was isolated using the RNeasy Mini Kit (Qiagen) from 18 cell lines (Supplementary Table 8 ) that were authenticated using Promega's Geneprint 10 kit that conforms with ATCC standard ASN-0002-2011, and verified as free from viable Mycoplasma by using Lonza's Mycoalert kit. cDNA was synthesized using SuperScript III (Invitrogen) and amplified using the Platinum SYBR Green qPCR SuperMix-UDG cocktail (Invitrogen). Two or three primer pairs were used for each gene and the mRNA levels for each sample were measured in technical triplicates for each primer set. The primer sequences are listed in Supplementary Table 13 . Experiments were performed using an ABI ViiA(TM) 7 System (Applied Biosystems), and data processing was performed using ABI QuantStudio Software V1.1 (Applied Biosystems). The average of Ct from all the primer pairs for each gene was used to calculate Δ Cт . The relative quantification of each mRNA normalized to that in 184A1 was performed using the comparative Ct method (Δ Δ Cт ) and is summarized in Supplementary Fig. 4 . siRNA silencing. 184A1, MCF7 and T47D cells obtained from the American Type Culture Collection were reverse-transfected with siRNAs targeting GOI or a NTC siRNA (consi; Shanghai Genepharma) with RNAiMAX (Invitrogen) according to the manufacturer's protocol. Verification of siRNA knockdown of gene expression by qPCR was performed 36 h after transfection.
Proliferation and colony-formation assays. For proliferation assays, MCF7 and T47D cells were trypsinized at 16 h post-transfection and seeded into 24-well plates to achieve ~10% confluency. Phase-contrast images were collected with IncuCyte ZOOM (Essen Bioscience) for seven days. Duplicate samples were assessed for cells treated with siRNAs against each GOI along with cells treated with NTC siRNA in the same plate. 184A1 cells were reverse-transfected in 96-well plates to achieve 50% confluence at 8 h after transfection. Two independent experiments were carried out for all siRNAs in all three cell lines. Each cell proliferation time course was normalized to the baseline confluency and analyzed in GraphPad Prism. The area under the curve was calculated for each concentration (n = 4) and used to calculate corrected proliferation (corrected proliferation (%) = 100 ± (relative proliferation in indicated siRNA− proliferation in NTC siRNA)/knockdown efficiency ('+ ' if the GOI promotes proliferation and '− ' if it inhibits proliferation)). For each gene, results from two siRNAs in two independent experiments were averaged and are summarized in Fig. 2 and Supplementary Fig. 6 . For colonyformation assays, the same number of GOI siRNA-transfected MCF7 cells was seeded in 6-well plates at 16 h after transfection to assay CFE at two weeks. All siRNA-treated cells were seeded in duplicate. Colonies (defined to consist of at least 50 cells) were fixed with methanol, stained with crystal violet (0.5% w/v), scanned and counted using ImageJ as batch analysis by a self-defined plug-in Macro. Corrected CFE (%) = 100 ± (relative CFE in indicated siRNA − CFE in NTC siRNA)/knockdown efficiency ('+ ' if the GOI promotes colony formation and '− ' if it inhibits colony formation). For each gene, results from two siRNAs in two independent experiments were averaged and are summarized in Fig. 2 and Supplementary Fig. 7 . P values were determined by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. 
Reporting

Data exclusions
Describe any data exclusions. We excluded samples from non-European descendants as this study focus on European descendants. We used standard quality control protocols to exclude samples with poor data quality.
Replication
Describe whether the experimental findings were reliably reproduced.
For gene expression prediction models, both internal (cross validations) and external validations were performed. Bonferroni correction was used to reduce type 1 errors in association analyses. For identified significant associations with breast cancer risk, we performed stratified analyses in the subsets of iCOGS, OncoArray and GWAS sets. Finally, in vitro assays were performed to evaluate the function of selected genes identified in the association analyses. The functional experiments for prioritized genes were replicated as described in the methods section. All siRNAs were dissolved and aliquoted to avoid more than one freezethaw cycle. All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. This is not relevant to our study, as our study is a genetic epidemiological study but not a randomized clinical trial.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For the in vitro functional experiments, the investigators were blinded to group allocation during data collection and analyses.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines were verified as free from viable Mycoplasma by the using Lonza's Mycoalert kit.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
